Deep Transcranial Magnetic Stimulation (TMS) is a novel patented technology, enabling non-invasive direct stimulation of deep neuronal pathways, with almost no side effects. This ability may be useful for basic research and a broad range of psychiatric and neurological applications.
Brainsway was founded in March 2003, and has exclusive rights on the Deep TMS technology developed by Dr. Abraham Zangen from the Weizmann Institute of Science. The safety and efficacy of neuronal activation at depth were proven in clinical trials. The company is supporting both clinical and basic research in animal models for advancing the use of the technology in research and medicine. Interim results of a clinical study in drug-resistant depression patients, show a significant improvement in most patients.
Visit www.brainsway.com for more information.